Stockreport

Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

Corbus Pharmaceuticals Holdings, Inc.  (CRBP) 
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: corbuspharma.com
PDF On track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026 Phase 1b data will build upon Phase 1a findings that demonstrated weight loss of nearly [Read more]